Evidence map›Paper›PMID 40662822›Full record

ArticleBioinformatics (Oxford, England)2025

Accurate PROTAC-targeted degradation prediction with DegradeMaster.

Jie Liu, Michael J Roy, Luke Isbel, Fuyi Li

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Designing the Proteome with Chemical Tools: Degrons and Beyond.Chembiochem : a European journal of chemical biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jie LiuSouth Australian Immunogenomics Cancer Institute (SAiGENCI), The University of Adelaide, Adelaide, South Australia 5005, Australia.ORCID 0000-0002-2800-608X
Michael J RoySouth Australian Immunogenomics Cancer Institute (SAiGENCI), The University of Adelaide, Adelaide, South Australia 5005, Australia.ORCID 0000-0003-0198-9108
Luke IsbelSouth Australian Immunogenomics Cancer Institute (SAiGENCI), The University of Adelaide, Adelaide, South Australia 5005, Australia.ORCID 0000-0002-5270-4347
Fuyi LiSouth Australian Immunogenomics Cancer Institute (SAiGENCI), The University of Adelaide, Adelaide, South Australia 5005, Australia.ORCID 0000-0001-5216-3213

Funding

Australia National Health and Medical Research Council 2041439Australian GovernmentSouth Australian immunoGENomics Cancer Institute
6 · The paper itself

Abstract

motivationProteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that can degrade "undruggable" protein of interest by recruiting E3 ligases and hijacking the ubiquitin-proteasome system. Some efforts have been made to develop deep learning-based approaches to predict the degradation ability of a given PROTAC. However, existing deep learning methods either simplify proteins and PROTACs as 2D graphs by disregarding crucial 3D spatial information or exclusively rely on limited labels for supervised learning without considering the abundant information from unlabeled data. Nevertheless, considering the potential to accelerate drug discovery, it is critical to develop more accurate computational methods for PROTAC-targeted protein degradation prediction.

resultsThis study proposes DegradeMaster, a semisupervised E(3)-equivariant graph neural network-based predictor for targeted degradation prediction of PROTACs. DegradeMaster leverages an E(3)-equivariant graph encoder to incorporate 3D geometric constraints into the molecular representations and utilizes a memory-based pseudolabeling strategy to enrich annotated data during training. A mutual attention pooling module is also designed for interpretable graph representation. Experiments on both supervised and semisupervised PROTAC datasets demonstrate that DegradeMaster outperforms state-of-the-art baselines, with substantial improvement of AUROC by 10.5%. Case studies show DegradeMaster achieves 88.33% and 77.78% accuracy in predicting the degradability of VZ185 candidates on BRD9 and ACBI3 on KRAS mutants. Visualization of attention weights on 3D molecule graph demonstrates that DegradeMaster recognizes linking and binding regions of warhead and E3 ligands and emphasizes the importance of structural information in these areas for degradation prediction. Together, this shows the potential for cutting-edge tools to highlight functional PROTAC components, thereby accelerating novel compound generation. AVAILABILITY AND IMPLEMENTATION: The source code and datasets are available at https://github.com/ABILiLab/DegradeMaster and https://zenodo.org/records/14715718.

Indexed as

Computational BiologyProteinsProteolysisSoftwareDeep LearningDrug DiscoveryHumansNeural Networks, ComputerUbiquitin-Protein LigasesProteinsUbiquitin-Protein Ligases

Identifiers

PMID40662822
PMCPMC12261415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.